Abstract: Recent state-based studies have shown an increased risk of opioid overdose death in Medicaid populations. To explore one side of risk, this study examines indicators of potential opioid inappropriate use or prescribing among Medicaid enrollees. We examined claims from enrollees aged 18-64 years in the 2010 Truven Health MarketScan® Multi-State Medicaid database, which consisted of weighted and nationally representative data from 12 states. Pharmaceutical claims were used to identify enrollees (n=359,368) with opioid prescriptions. Indicators of potential inappropriate use or prescribing included overlapping opioid prescriptions, overlapping opioid and benzodiazepine prescriptions, long acting/ extended release opioids for acute pain, and high daily doses. In 2010, Medicaid enrollees with opioid prescriptions obtained an average 6.3 opioid prescriptions, and 40% had at least one indicator of potential inappropriate use or prescribing. These indicators have been linked to opioid-related adverse health outcomes, and methods exist to detect and deter inappropriate use and prescribing of opioids.
among the Medicaid population. [8] [9] [10] This population is of concern because it has, on average, higher levels of mental health and substance abuse disorders than the general population 9, 11 and thus potentially greater risk for adverse outcomes with opioids. Indeed, two states have reported an increased risk of opioid overdose death in their Medicaid populations. 12, 13 This study expands the literature in this area by examining multiple indicators of use and potential misuse of opioids among Medicaid patients using one of the largest fully-integrated health insurance claims databases in the United States. The objective is to describe the volume of opioid prescribing among Medicaid enrollees, and provide an index of measures to describe potential misuse or inappropriate prescribing.
Methods
Data source. We conducted secondary data analyses of the Truven Health MarketScan® Multi-State Medicaid database, which consisted of weighted and nationally representative data from 12 geographically dispersed states. The MarketScan Medicaid database contains standardized, fully integrated, enrollee-level de-identified claims across in patient, outpatient, and prescription drug services for both fee-for-services and capitation plans. Our analysis primarily drew data from pharmaceutical claims in 2010 for filled prescriptions, which included outpatient drug name, therapeutic class, national drug code, days of supply, and quantity for about 1.38 million Medicaid enrollees aged 18-64 years. In addition, the outpatient service claims and inpatient admission records were used to identify the underlying pain diagnoses related to opioid use. Inpatient admission records were employed only to identify the diagnoses associated with opioid prescriptions prescribed to enrollees at discharge. Drugs administered during hospitalizations were not included. No personal identifying information was available in the database, and this study did not require human subjects' review.
Study population. From the pharmaceutical claims we identified 3,534,564 opioid prescriptions for the 1.38 million enrollees aged 18-64 years ( Figure 1 ). We excluded 704,624 opioid prescriptions for non-continuously enrolled Medicaid recipients in 2010; 173,125 opioid prescriptions that lacked the dispensing information necessary for the calculation of outcome indicators; and 67,073 opioid prescriptions that were refill prescriptions that could not be linked to their original diagnoses. We also excluded 68,642 opioid prescriptions for enrollees under institutional long-term-care, and 218,678 for enrollees with a cancer diagnosis in their outpatient or inpatient service claims. Cancer diagnosis were based on International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes including 338.3; 140-172.9; 174-215.9; 217-229.10; and 235-239.9. Finally, roughly 1% (37,405) of the opioid prescriptions were for buprenorphine products and were excluded due to their primary use for the treatment of opioid dependence (methadone received at narcotic treatment centers is excluded by default given that we did not capture narcotic treatment center claims). This selection process resulted in 2,265,017 opioid prescriptions for 359,368 Medicaid enrollees as our final study population (see Figure 1) . A list of opioids analyzed is available upon request, and morphine equivalent conversion factors used have been previously described.
that are specific to certain types of pain, we linked opioid prescription claims to the diagnoses on outpatient or inpatient service claims by matching enrollee ID and the date of service in these claims. Consistent with the existing literature, 15 we linked opioid prescriptions to the outpatient services or inpatient discharges that occurred within 14 days of the prescription dispense dates. If multiple outpatient or inpatient records existed within this interval, we linked to the one that occurred on the day closest to the drug dispense dates. When inpatient and outpatient dates of service overlapped, we used the outpatient claims for the linkage. Prescription refills were assigned the diagnoses on the original prescriptions. We successfully linked 1,772,632 (78.3%) of the 2,265,017 opioid prescriptions to diagnoses for 323,879 enrollees (90% of the overall study population). Of the remaining 21.7% of prescriptions, 19.5% could not be linked because the outpatient services or inpatient discharges had occurred more than 14 days prior to the prescription dispensing date or in 2009; 2.2% could not be linked because MarketScan did not have the enrollee's outpatient service claims.
Outcome indicators. We adapted outcome indicators that had been identified by expert panels and clinical guidelines [16] [17] [18] [19] [20] [21] [22] and validated by their association with abuse of overdose. [23] [24] [25] [26] These indicators captured both general opioid use as well as potential misuse by patients or inappropriate prescription practices by providers.
At the enrollee level, indicators of general opioid use included the total number of opioid prescriptions, total days' supply of opioids, and medical diagnoses (such as acute pain, other pain, or both) associated with opioid prescriptions. Acute pain and other pain diagnoses were based on ICD-9-CM codes ( Table 1 footnote b and c). Indicators of potential misuse or inappropriate prescription practices consisted of: (1) opioid overlap, defined as opioid prescriptions that overlap seven or more days (including early refills); (2) opioid and benzodiazepine overlap, defined as opioid and benzodiazepine prescriptions that overlap seven or more days; (3) high daily opioid dose, defined as a prescribed daily dose of 100 morphine milligram equivalents (MMEs) or greater; and (4) rapid opioid dose escalation, measured as having a 50% or greater increase in mean MMEs per month twice consecutively during the year.
Three indicators specific to long-acting/ extended-release (LA/ ER) prescriptions were examined given their elevated risk for addiction and initiation abuse: (1) LA/ ER opioid prescriptions written for acute pain conditions; (2) overlapping LA/ ER opioid prescriptions; and (3) LA/ ER prescriptions obtained by an opioid "naïve" person, defined as a person who had no prescription for an opioid for at least 60 days prior to that for an LA/ ER opioid.
At the prescription level, indicators of general opioid use included the number of days' supply and the prescribed daily doses for opioid prescriptions for acute, back, and other pain. Back pain included both acute and other back pain and was based on ICD-9-CM codes recommended by the American College of Occupational and Environmental Medicine (ACOEM) practice guidelines. 27 Indicators of potential inappropriate prescription practices are the same as those described for enrollees though expressed in number of prescriptions.
Statistical analysis. We calculated the distributions of various levels of usage among all enrollees receiving an opioid prescription overall, by sex, and by pain type. The prevalence for indicators of potential misuse by patients or inappropriate prescription practices by providers was calculated as both a percentage of enrollees and a percentage of prescriptions. We used t-tests or chi-square tests for comparisons by sex. b. Acute pain was determined by whether the enrollee had a diagnosis of a disease or an injury or a surgical procedure that could cause acute pain. Diagnoses for acutely painful diseases and injuries and their ICD9-CM codes were: sickle cell with crisis (282.62); acute pain (338.11,338.12,338.18,338.19); dental abscess with sinus (522.5); dental abscess without sinus (522.7); gallstone (574); acute pancreatitis (577); kidney stone (592); pathological fracture (733.1); acute injury (800-904.9); other acute injury (910-959.9); external cause of injury codes (E800-E849.9; E880-E909.9; E916-E928.9; E953-E968.9; E970-E976.9; E983-E999.9). After the exclusion of minor procedures, surgical procedures included: excision of breast tissue; other major skin, breast, or musculoskeletal surgeries; other major respiratory, cardiovascular, hemic and lymphatic, digestive, eye/ ocular, ear/ auditory or urinary procedures; repair of inguinal hernia procedures; major male genital procedures; dilation and currettage; major female genital procedures; decompression, carpal tunnel surgery; major endocrine system, and nervous system procedures; cataract removal; other major surgery procedures; cesarean section deliveries; major maternity procedures and related care; and dental, or major restorative surgery. e. Causes for opioid use were unknown because these enrollees' opioid prescriptions could not be linked to any outpatient/ inpatient service claims.
scriptions (53%) in 2010. Notably, 7% of the study population had 20 or more opioid prescriptions during the data year-with more than 800 enrollees receiving 50 or more opioid prescriptions (data not shown). Just under one half of the male recipients (49.4%) received less than 30 total days' supply of opioids, and about 37.1% received more than 90 days' supply of opioids in 2010. Among women, nearly 60% received less than a 30 days' supply, and 27.1% received more than 90 days' supply of opioids during 2010. Over 13,000 (14%) male opioid recipients received 200-364 days of opioids in the past year, and 11,326 (12%) received more than a 365 days' supply. For women nearly 27,000 (10%) received 200-364 days, and 21,269 (8%) received more than 365 days (data not shown).
We were able to identify the associated medical diagnoses for opioid prescriptions for 90% of the overall study population; 22% of the recipients obtained opioids for acute pain conditions only; 17.7% received opioids for other pain conditions only; and 29.7% obtained opioids for both acute and other pain conditions. Another 20.6% of the recipients received opioid prescriptions for diagnoses not included in the lists of acute or other pain conditions (e.g., acute pharyngitis, chronic airway obstruction, unspecified dental caries, urinary tract infection, and other general symptoms)
The most common indicator of inappropriate use was having an opioid/ benzodiazepine overlap (Table 2) ; 22.6% of the opioid recipients had at least one such event during the study period. Seventeen percent of the study population had daily doses of 100 MMEs or higher per opioid prescription at least once during the study period, and of those recipients, 17% had daily doses of 100 MMEs or higher for more than 90 days (data not shown). Roughly 1% of the opioid recipients had opioid dose escalation. Overall 40.7% of the opioid recipients had at least one indicator of inappropriate use: one-quarter (24.7%) had one indicator, 11% had two and 5% had three. Among those who had LA/ ER opioid prescriptions, 21.8% received LA/ ER opioids for an acute pain condition at least once.
Prescription level indicators. Among the 1,772,632 prescriptions that were linked to diagnoses, about 16.5% of them were written for acute pain conditions alone, and a higher proportion (34.9%) were for other pain alone. Ten percent were associated with both acute pain and other pain conditions, and 15.3% were associated with back pain diagnoses. The remaining 38.5% of the prescriptions were linked to diagnoses not included in the lists of acute or other pain conditions (as noted above).
The mean days' supply for acute, other, and back pain was nine, 20, and 21 days, respectively (Table 3) . For acute pain, 70.6% of prescriptions were written for nine or fewer days, and 14% were written for 30 or more days. The mean daily opioid dose for prescriptions for acute pain was higher for men (53.1 MME) than females (49 MME). Notably, 9% of prescriptions for acute pain were written for 100 MME per day or more.
For other pain, nearly half (48.4%) of the prescriptions were for 30 or more days. The mean daily dose for opioid prescriptions for other pain was higher for males (62 MME) than females (52.6 MME). While other pain conditions were treated for longer periods of time than acute pain conditions, the average dosage employed was comparable to that used for acute pain. For back pain, over half of the prescriptions were for 30 days or more. The mean daily dose for back pain was similar to that for other pain at 61.8 MME for males and 51.8 MME for females.
As for indicators of potential inappropriate prescribing, roughly 30% of opioid a. Days' supply of one opioid prescription overlaps with another opioid prescription for at least 7 days for a given enrollee. b. Days' supply of one opioid prescription overlaps with one or more benzodiazepine prescription for at least 7 days for a given enrollee. c. ≥100 morphine milligram equivalents (MMEs) d. Having a 50% or greater increase in mean MME per month twice consecutively during the year. e. The numbers of enrollees who received LA/ ER opioids were 10,027 and 16,614 for males and females, respectively. Table 3 .
INDICATORS FOR GENERAL PRESCRIPTION PRACTICES AND POTENTIAL INAPPROPRIATE PRACTICES FOR OPIOID ANALGESICS ACCORDING TO ACUTE, CHRONIC, OR BACK PAIN DIAGNOSIS, MEDICAID ENROLLEE PRESCRIPTIONS BY GENDER, MARKETSCAN 2010
Prescriptions for *Difference between males and females is significant p<.01 a. Acute pain was determined by whether the enrollee had a diagnosis of a disease or an injury or a surgical procedure that could cause acute pain. Diagnoses for acutely painful diseases and injuries and their ICD9-CM codes were: sickle cell with crisis (282.62); acute pain (338.11,338.12,338.18,338.19); dental abscess with sinus (522.5); dental abscess without sinus (522.7); gallstone (574); acute pancreatitis (577); kidney stone (592); pathological fracture (733.1); acute injury (800-904.9); other acute injury (910-959.9); external cause of injury codes (E800-E849.9; E880-E909.9; E916-E928.9; E953-E968.9; E970-E976.9; E983-E999.9). After the exclusion of minor procedures, surgical procedures included: excision of breast tissue; other major skin, breast, or musculoskeletal surgeries; other major respiratory, cardiovascular, hemic and lymphatic, digestive, eye/ ocular, ear/ auditory or urinary procedures; repair of inguinal hernia procedures; major male genital procedures; dilation and currettage; major female genital procedures; decompression, carpal tunnel surgery; major endocrine system, and nervous system procedures; cataract removal; other major surgery procedures; cesarean section deliveries; major maternity procedures and related care; and dental, or major restorative surgery. e. Days' supply of one opioid prescription overlaps with one or more benzodiazepine prescription for at least 7 days for a given enrollee. f. ≥100 morphine milligram equivalents (MMEs). g. The numbers of total LA/ ER opioids prescriptions were 82,199 and 130,731 for males and females respectively, and percentages are based on those numbers. It is important to note that most of the prescriptions for opioids appeared to fall within the range of appropriate use and standard care. Nevertheless, there is cause for concern. The opioid misuse indicators examined in this study have been linked to opioid-related adverse health outcomes in other studies. Increased numbers of opioid prescriptions, overlapping or early refill prescriptions, dose escalation, and greater days' supply of opioids have all been associated with increased risk of clinically recognized abuse. 23, 24 Higher daily dose has been associated with misuse, emergency department visits, and overdoses. [24] [25] [26] Acute pain is not an indication for an LA/ ER opioid, and such use is considered inappropriate by clinical guidelines 19 and yet in this study, 21.8% of those who received a LA/ ER opioid, did so for acute pain. Further, most LA/ ER opioids carry warnings against initiation among opioid-naïve patients.
The New York City Department of Health and Mental Hygiene has recommended no more than a seven-day supply of opioids for acute pain, 28 however, in this study 15.3% of opioid prescriptions for acute pain were prescribed for 10-29 days, and 14% were for 30 or more days. For severe, acute low back pain specifically, the American College of Occupational and Environmental Medicine practice guidelines only recommend opioids on a limited basis, with treatment to last no more than two weeks. 27 Opioids are not recommended to be used for long-term treatment of chronic back pain. 29 In this study, over half (51.7%) of opioid prescriptions for back pain were written for 30-49 days, more than recommended by expert consensus.
While women make up 58% of the total Medicaid population, they were 74% of our study population. Our study is consistent with previous literature in finding that women constitute the majority of users of opioids both alone and in combination with benzodiazepines. 15 We found that the mean number of opioid prescriptions differed by one script per year between female and male opioid recipients (6.0 and 7.1 respectively); however, the annual mean days' supply was much lower for women than men (96.4 and 133 respectively). Despite the fact that men are more likely to use prescription painkillers non-medically, to abuse opioids, and to die from drug overdoses involving opioids, 30, 31 the percentage increase in the number of recent deaths from prescription painkillers is greater among women. 32 The prevalences of indicators of possible misuse in this study were only slightly lower among women in this Medicaid population.
Limitations. Our study has several limitations. The potential inappropriate indicators have been validated by their association with misuse or abuse in other studies. In some cases, of course, such behaviors represent appropriate care for patients not misusing drugs, e.g., overlapping prescriptions resulting from changes in dosage or in drug type as a result of some adverse effect, or use of short-acting opioids for break through pain in patients receiving long-acting or extended release opioids. Claims data were designed to support financial transactions rather than to capture clinical information, and as such may suffer some inherent flaws, however they remain an important source of health data. 33 Pharmacy claims represent filled prescriptions reimbursed rather than actual drug consumption and do not capture prescriptions paid for with cash. Prescriber information was incomplete to the extent that analyses based on prescriber data would have severe limitations. Last, relying on ICD-9CM codes to determine the reason for a prescription is subject to error. Many conditions are painful but are not usually counted among common causes of pain. Type of pain might also have been misclassified. While these analyses are unable to determine whether patient or prescriber was the source of any potential prescribing or use problems, our analysis represents a comprehensive look at opioid use and potential inappropriate among Medicaid recipients in the largest fully-integrated commercial claims database in the United States, and they point to situations that warrant further investigation to determine causal factors.
While the majority of opioid prescriptions among this population might have been appropriate, a substantial number were prescribed in a manner that suggests inappropriate patient use or provider prescribing practice. Robust prescription opioid utilization review programs using integrated claims data, similar to our analyses, might reduce misuse and overdose risk, help improve quality of care, and reduce unnecessary health care costs. 6, 34 Such programs, combined with other systematic prevention strategies such as prescription drug monitoring programs, that track information on controlled substance prescriptions filled in a state, and use of opioid prescribing guidelines may assist providers to address improper opioid use, reduce the risk of adverse outcomes, and improve the appropriate prescribing of opioid medications.
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